Novo Nordisk ASWBO:NNO2 -1.23%71 3-Year Dividend Growth Rate is 27.80% as of Mar. 2026, which is 76% above its 10-year median of 15.80. GuruFocus rates WBO:NNO2 with a GF Score™ of 71/100 and a GF Value™ of €121.33 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 351 Drug Manufacturers companies, Novo Nordisk AS ranks better than 79.2% on this metric.
The historical rank and industry rank for Novo Nordisk AS's 3-Year Dividend Growth Rate or its related term are showing as below:
WBO:NNO2'
s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -30.8 Med: 15.8 Max: 37.7
Current: 27.8
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Novo Nordisk AS was 37.70% per year. The lowest was -30.80% per year. And the median was 15.80% per year.
WBO:NNO2's 3-Year Dividend Growth Rate is ranked better than 79.2% of 351
companies
in the Drug Manufacturers industry
Industry Median: 7.7
vs WBO:NNO2: 27.80
During the past 12 months, Novo Nordisk AS's average Dividends Per Share Growth Rate was 2.60% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 27.80% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 23.80% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 12.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
During the past 13 years, the highest Dividend Payout Ratio of Novo Nordisk AS was 0.62. The lowest was 0.39. And the median was 0.46.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
Novo Nordisk AS Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
DKK 7.950000
2026-03-27
2026-03-30
2026-03-31
Cash Dividend
semi-annually
DKK:EUR 0.133876
DKK 3.750000
2025-08-15
2025-08-18
2025-08-19
Cash Dividend
semi-annually
DKK:EUR 0.134477
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Novo Nordisk AS's Dividend Yield (%) for Today is calculated as
Current Share Price is €43.055.
Novo Nordisk AS's Dividends per Share for the trailing twelve months (TTM) ended in Today is €1.56860295.
During the past 13 years, the highest Dividend Yield of Novo Nordisk AS was 5.10%. The lowest was 0.78%. And the median was 2.03%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS 3-Year Dividend Growth Rate Related Terms>
WBO:NNO2 vs LLY, JNJ, ABBV: 3-Year Dividend Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS 3-Year Dividend Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's 3-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's 3-Year Dividend Growth Rate falls into.
Novo Nordisk AS 3-Year Dividend Growth Rate Calculation
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Dividend Growth Rate of 27.80% mean?
Novo Nordisk AS (WBO:NNO2) has a 3-Year Dividend Growth Rate of 27.80% as of Mar. 2026. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Novo Nordisk AS and its competitors. This is 76% above median its historical median of 15.80. According to the industry distribution chart, Novo Nordisk AS ranks #73 out of 351 companies in the Drug Manufacturers industry, placing it in the top 20.8%.
Is Novo Nordisk AS's 3-Year Dividend Growth Rate too high?
Novo Nordisk AS's current 3-Year Dividend Growth Rate of 27.80% is 76% above median its 10-year median of 15.80. The Drug Manufacturers industry median 3-Year Dividend Growth Rate is 7.70. Novo Nordisk AS's value of 27.80% is 261% above this industry median. Based on the distribution chart, Novo Nordisk AS ranks #73 out of 351 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novo Nordisk AS has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's 3-Year Dividend Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #73 out of 351 companies for 3-Year Dividend Growth Rate. This places Novo Nordisk AS in the top 21% of its industry — outperforming the majority of peers. The industry median 3-Year Dividend Growth Rate is 7.70. Novo Nordisk AS's value of 27.80% is 261% above this benchmark. While the company's 10-year median is 15.80 vs. the industry median of 7.70, Novo Nordisk AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Drug Manufacturers company?
The median 3-Year Dividend Growth Rate among Drug Manufacturers companies is 7.70, based on 351 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current 3-Year Dividend Growth Rate of 27.80% is 261% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median 3-Year Dividend Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current 3-Year Dividend Growth Rate is 27.80%, which is 76% above median its own 10-year median of 15.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (WBO:NNO2) is currently considered Significantly Undervalued. The stock's GF Value™ is €121.33, compared to a current price of €43.06 — trading 64.5% below its estimated fair value. The current 3-Year Dividend Growth Rate is 27.80%, which is 76% above median its 10-year median of 15.80 and 261% above the Drug Manufacturers industry median of 7.70. Novo Nordisk AS's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For Novo Nordisk AS (WBO:NNO2), the current 3-Year Dividend Growth Rate is 27.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of €43.06 is trading 64.5% below its estimated GF Value™ of €121.33.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for WBO:NNO2:
3-Year Dividend Growth Rate: 27.80% (76% above median its 10-year median of 15.80)
GF Value™: €121.33 vs. price of €43.06 (64.5% below fair value)
Industry Position: 261% above the Drug Manufacturers median (#73 of 351)
No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
71GF Score
Get the complete analysis for WBO:NNO2
3-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:NNO2 has been successfully added to your 